Mesoblast to Conduct Pivotal Ryoncil Trial in Adults With Severe Acute Graft Versus Host Disease

MT Newswires Live11-21

Mesoblast (ASX:MSB) will collaborate with the Blood and Marrow Transplant Clinical Trials Network on a pivotal trial of Ryoncil as part of a first-line regimen in adults with severe acute graft versus host disease refractory to corticosteroids, according to a Friday Australian bourse filing.

The patients will be randomized in the trial as early as possible after corticosteroid refractoriness to receive ruxolitinib alone or combined with Ryoncil to give them the best chance of survival.

The trial protocol will be provided to the US Food and Drug Administration to initiate enrollment in the first quarter of 2026. Mesoblast recently met with the US FDA to discuss the most appropriate patient population and timing of treatment in a pivotal trial of Ryoncil for adults with severe acute graft versus host disease.

Ryoncil is already approved by the FDA in children and adolescents.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment